Celltrion to Strengthen Global Partnerships at CPHI... Expanding Strategic Collaboration

Discovering New Partners in Raw Materials and CMO Sectors
Exploring Collaboration in Novel Modalities and Automated Process Technologies

Celltrion will participate in 'CPHI (Convention on Pharmaceutical Ingredients) Worldwide 2025,' which will be held in Frankfurt, Germany from October 28 to 30 (local time), to expand its global partnerships.

The Celltrion booth to be set up at 'CPHI Worldwide 2025' held in Frankfurt, Germany from the 28th to 30th. Celltrion

Now in its 36th year, CPHI is the world’s largest pharmaceutical and biopharmaceutical industry exhibition, bringing together more than 60,000 industry experts from over 170 countries. Since 2022, Celltrion has set up an exclusive booth at the exhibition every year, continuing its efforts to strengthen global partnerships and enhance its brand presence.

This year, Celltrion will again install a large exclusive booth of approximately 202 square meters (about 61 pyeong) in the main hall, showcasing its global competitiveness and technological capabilities. The booth will feature dedicated meeting rooms and open meeting spaces, and its size has been expanded compared to last year to facilitate smoother partnerships. On-site, the company plans to conduct brand promotion activities by offering souvenirs and hosting a variety of interactive events for booth visitors.

In particular, Celltrion aims to strengthen its network with existing partners in areas such as overseas raw material supply and contract manufacturing (CMO), while also accelerating the acquisition of new partners. As demand for production continues to rise with the expansion of new product lines in the global market, the company’s strategy is to further strengthen partnerships to stably secure its supply chain.

This year, Celltrion has expanded its portfolio by successively launching new biosimilar products in the global market, including 'Stekyma' (ustekinumab) and 'Aptozma' (tocilizumab) for autoimmune diseases, 'Stovoclo-Ocenbelt' (denosumab) for bone diseases, and 'Omriclo' (omalizumab) for skin diseases. Accordingly, the company is actively working to enhance supply stability and strengthen its sales and marketing capabilities through collaboration with competitive global partners.

In addition, Celltrion plans to explore global collaboration opportunities in new business areas based on novel modalities and automated process technologies. Through these efforts, the company aims to closely monitor the latest trends in the industry, secure potential partners with core competencies, and seek out new market opportunities.

A Celltrion official stated, "This year, by participating in CPHI, one of the key events in the global pharmaceutical and biopharmaceutical industry, we will actively promote Celltrion's brand value and technological competitiveness, while further expanding our cooperation with promising global companies. Based on our expanded product portfolio, we will not only strengthen our production infrastructure but also seek strategic partnerships in future growth sectors to further solidify our position in the global market."

This content was produced with the assistance of AI translation services.